Parathyroid imaging with [99mTc]Tc-MIBI SPECT/CT — unexpected findings of bone marrow involvement of non-Hodgkin’s lymphoma by Kunikowska, Jolanta & Królicki, Leszek
271
CliniCal vignette
C
l
in
iC
a
l
 v
ig
n
e
t
t
e
Parathyroid imaging with [99mTc]Tc-MIBI SPECT/CT 
— unexpected findings of bone marrow involvement 
of non-Hodgkin’s lymphoma 
Jolanta Kunikowska, Leszek Królicki
Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland 
Key words: MIBI; non-Hodgkin’s lymphoma; small B-cell lymphoma; bone marrow
Endokrynologia Polska
DOI: 10.5603/EP.a2020.0023
Volume/Tom 71; Number/Numer 3/2020
ISSN 0423–104X
Hyperparathyroidism is a condition caused by in-
creased secretion of the parathormone (PTH), which 
plays an important role in calcium homeostasis. Para-
thormone raises the serum calcium level by the renal 
absorption of calcium, decreasing reabsorption of 
phosphate, and stimulating osteoclasts. The second 
important player in calcium homeostasis is vitamin D3 
(VitD3). The main function of 1,25(OH)2D3, the active 
form of VitD3, is to increase calcium absorption from 
the intestine. Low 1,25(OH)2D3 status leads to reduced 
efficiency in intestinal calcium absorption, which causes 
increased secretion of PTH. 
Primary hyperparathyroidism is considered to be 
present when serum calcium is elevated and PTH is 
increased or inappropriately normal. From the litera-
ture review, it can be seen to be primarily the result of 
a parathyroid adenoma (80–85% of cases), hyperplasia 
(10–15% of cases), or (albeit rarely) parathyroid carci-
noma (0.5–1% of cases). 
Surgical removal of the hypersecreting gland is the 
primary treatment; hence, localisation of the hyperfic-
tional parathyroid before it is most important. 
[99mTc]Tc-MIBI subtraction imaging or washout imag-
ing is currently the method of choice for parathyroid 
localisation, with  the reported sensitivity ranging from 
80% to 90%. The addition of single-photon emission 
computed tomography (SPECT) and more recently 
SPECT/CT improves the anatomical localisation and 
helps in the differentiation of the parathyroid from the 
thyroid lesions. 
A 72-year-old man, diagnosed previously with small 
B-cell lymphoma, underwent [99mTc]Tc-MIBI examina-
tion due to suspicion of hyperparathyroidism based on 
endocrinology consultation (biochemical examination: 
hypercalcaemia  Ca2+ 1.31 mmol/L  n: 1.15–1.29 mmol/L, 
PTH 235 pg/mL n: < 65 pg/mL, and Vit D3 11.2 ng/mL 
n: > 30 ng/mL). Previously performed ultrasound 
(US) was described as unremarkable, with no typical 
sign of parathyroid, multiple enlarged lymph nodes 
were seen. 
As a standard procedure subtraction [99mTc]NaTcO4 
(A)/[99mTc]Tc-MIBI (D — subtraction), [99mTc]Tc-MIBI dual 
phase (B — [99mTc]Tc-MIBI early, C — [99mTc]Tc-MIBI late 
image), and early SPECT/CT was performed (E-MIP).  
The dual-phase (B, C) and subtraction examination 
(D) did not reveal typical uptake for hyperfunctional 
parathyroid. On early and late [99mTc]Tc-MIBI imaging 
surprisingly diffuse uptake in the locus of bone was 
seen (B, C).
SPECT/CT image showed increased uptake in two 
lesions below the left lobe of the thyroid (F, G). Also, 
enlarged neck and axillary lymph nodes were found, 
some with increased tracer uptake (H) and diffuse 
increased uptake in the bone in the field of examina-
tion (E, H). 
Because of uptake not only in two lesions below 
the left lobe of thyroid, but also in some of the neck 
and axillary lymph nodes, the SPECT/CT examination 
was considered ambiguous. Fine needle biopsy of the 
suspected lesion confirmed involvement of the primary 
process lymph node. The bone marrow biopsy revealed 
only 10% bone marrow involvement.  
In the PET era the young generation of physicians 
have forgotten about the possibility of using differ-
ent tracers in oncological disease. [99mTc]Tc-MIBI, 
originally developed for scintigraphic evaluation 
of myocardial blood flow, has also been applied 
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to detect functional P-gp expression and used for 
imaging several types of malignant cells including 
non-Hodgkin’s lymphoma, with high diagnostic ac-
curacy up to 94% [1]. Moreover, the uptake, washout 
rate, and retention of [99mTc]Tc-MIBI could be helpful 
in the identification of drug resistance; patients with 
negative or decreased radiotracer activity tend to 
have unfavourable responses to chemotherapy com-
pared to those with prominent radiotracer accumula-
tion, irrespective of lymphoma type [2]. Also, a later 
scan (180 min after injection) could provide a more 
accurate prediction of chemoresistance than an early 
scan (30 min after injection) [3]. The involvement of 
bone marrow in multiple myeloma and correlation 
with in vitro and in vivo uptake was described by 
Fonti at al. [4, 5]. 
In the presented case [99mTc]Tc-MIBI showed much 
greater bone marrow involvement than was shown 
by the biopsy, which resulted in the change of treat-
ment scheme. The patient underwent chemotherapy 
(R-CHOP) with partial response. Visible uptake in the 
late phase of [99mTc]Tc-MIBI examination performed 
during standard procedure examination predicted the 
chemosensitivity. In follow-up, normalisation of Ca2+ 
level and decrease of PTH was observed; hence, the 
increased level of PTH was probably associated with 
low VitD3. 
Nowadays, this is a surprising image of small B-cell 
lymphoma in the [99mTc]Tc-MIBI examination. 
Figure 1. Parathyroid scintigraphy. A. [99mTc]NaTcO4; B. [99mTc]Tc-MIBI early phase; C. [99mTc]Tc-MIBI late image; D. Subtraction 
[99mTc]Tc-MIBI/[99mTc]NaTcO4; E. MIP SPECT; F. Fusion SPECT/CT; G. CT; H. Fusion SPECT/CT
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